TCR2 Therapeutics Inc. – NASDAQ:TCRR

Add to watchlist

Market closed

Open in about 10 hours

-12.71%

month

+43.64%

quarter

-27.85%

year

Market Cap	58.10M
Enterprise value	80.78M

P/E	-0.38
EV/Sales	N/A
EV/EBITDA	-0.54
Price/Sales	N/A
Price/Book	0.42
PEG ratio	0.03
EPS	-4.2

Revenue	N/A
EBITDA	-95.74M
Income	-163.09M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

TCR2 Therapeutics Inc. (NASDAQ:TCRR): Profit margin
Jun 2022	0	-31.60M
Sep 2022	0	-30.59M
Dec 2022	0	-60.50M
Mar 2023	0	-40.39M

TCR2 Therapeutics Inc. (NASDAQ:TCRR): Debt to assets
Jun 2022	308044000	81.78M	26.55%
Sep 2022	272927000	74.37M	27.25%
Dec 2022	208236000	67.37M	32.36%
Mar 2023	151513000	50.18M	33.12%

TCR2 Therapeutics Inc. (NASDAQ:TCRR): Cash Flow
Jun 2022	-19.53M	-10.33M	-47K
Sep 2022	-25.83M	35.56M	72K
Dec 2022	-24.95M	3.65M	41K
Mar 2023	-40.01M	21.68M	24K

TCR2 Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

TCR2 Therapeutics Inc. (NASDAQ:TCRR): Employee count
Aug 2023	58
Sep 2023	58
Oct 2023	58
Nov 2023	58
Dec 2023	58
Jan 2024	58
Feb 2024	58
Mar 2024	58
Apr 2024	58
May 2024	58
Jun 2024	58
Jul 2024	58

TCR2 Therapeutics
Hedge Funds Holdings Q1 2023

31.82% -23.01%

of TCRR is owned by hedge funds

40 -19

hedge funds hold TCRR stock

12.29M -8.88M

shares is hold by hedge funds

TCRR hedge funds holdings changes

TCR2 Therapeutics
Insider Trading

TCR2 Therapeutics Inc. (NASDAQ:TCRR): Insider trades (number of shares)
Period	Buy	Sel
Dec 2022	0	147061
May 2023	418513	140340

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	22 May 2023	GADICKE ANSBERT director, 10 percent owner: director, 10 percent owner:	Common Stock	70,170	$1.88	$131,920
Sale	22 May 2023	MPM ASSET MANAGEMENT LLC 10 percent owner 10 percent owner	Common Stock	70,170	$1.88	$131,920
Purchase	12 May 2023	TANG KEVIN C 10 percent owner	Common Stock	6,183	$1.95	$12,057
Purchase	11 May 2023	TANG KEVIN C 10 percent owner	Common Stock	38,765	$1.95	$75,592
Purchase	10 May 2023	TANG KEVIN C 10 percent owner	Common Stock	6,774	$1.95	$13,209
Purchase	9 May 2023	TANG KEVIN C 10 percent owner	Common Stock	20,141	$1.95	$39,275
Purchase	8 May 2023	TANG KEVIN C 10 percent owner	Common Stock	57,073	$1.95	$111,292
Purchase	5 May 2023	TANG KEVIN C 10 percent owner	Common Stock	95,759	$1.9	$181,942
Purchase	5 May 2023	TANG KEVIN C 10 percent owner	Common Stock	71,064	$1.94	$137,864
Purchase	4 May 2023	TANG KEVIN C 10 percent owner	Common Stock	104,241	$1.86	$193,888

TCRR insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Compositions and methods for TCR reprogramming using fusion proteins Filling date: 2 Aug 2017 Issue date: 8 Feb 2022	2 Aug 2017	8 Feb 2022
Application	Application COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS Filling date: 8 Mar 2019 Issue date: 25 Nov 2021	8 Mar 2019	25 Nov 2021
Application	Application COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING TARGET SPECIFIC FUSION PROTEINS Filling date: 26 Jul 2019 Issue date: 14 Oct 2021	26 Jul 2019	14 Oct 2021
Application	Application COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS Filling date: 30 Aug 2019 Issue date: 19 Aug 2021	30 Aug 2019	19 Aug 2021
Grant	Grant Utility: Compositions and methods for TCR reprogramming using fusion proteins Filling date: 10 Aug 2020 Issue date: 10 Aug 2021	10 Aug 2020	10 Aug 2021
Application	Application COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS Filling date: 10 Jun 2019 Issue date: 8 Jul 2021	10 Jun 2019	8 Jul 2021
Application	Application ENGINEERED T CELLS FOR THE TREATMENT OF CANCER Filling date: 21 Dec 2017 Issue date: 24 Jun 2021	21 Dec 2017	24 Jun 2021
Grant	Grant Utility: Compositions and methods for TCR reprogramming using fusion proteins Filling date: 10 Aug 2020 Issue date: 8 Jun 2021	10 Aug 2020	8 Jun 2021
Application	Application COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS Filling date: 13 Jun 2018 Issue date: 18 Mar 2021	13 Jun 2018	18 Mar 2021
Application	Application COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS Filling date: 10 Aug 2020 Issue date: 19 Nov 2020	10 Aug 2020	19 Nov 2020

TCR2 Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2019 13 May 2019	Q1 2019 Earnings Call Transcript

TCRR earnings call transcripts

TCR2 Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Garry E. Menzel M.B.A., Ph.D. (1964) Pres, Chief Executive Officer & Director	61		$941,230
Dr. Alfonso Quintás Cardama M.D. (1971) Chief Medical Officer	54		$678,580

TCR2 Therapeutics
Latest News

Tuesday, 7 March 2023
11:35	5 Penny Stocks To Buy According To Analysts, Targets Up To 952%	PennyStocks
Monday, 6 March 2023
10:45	Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?	InvestorPlace
Wednesday, 15 February 2023
06:00	TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path	Seeking Alpha
Wednesday, 8 February 2023
06:45	TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023	GlobeNewsWire
Wednesday, 23 November 2022
06:45	TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference	GlobeNewsWire
Friday, 11 November 2022
11:18	Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)	Zacks Investment Research
Tuesday, 27 September 2022
16:15	TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors	GlobeNewsWire
Monday, 26 September 2022
16:15	TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit	GlobeNewsWire
Thursday, 18 August 2022
06:58	TCR² Therapeutics: Betting On A Solid Reversal	Seeking Alpha
Wednesday, 1 June 2022
06:45	TCR² Therapeutics to Participate in Two Upcoming Conferences in June	GlobeNewsWire
Wednesday, 9 February 2022
06:45	TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference	GlobeNewsWire
Thursday, 13 January 2022
11:33	Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks	Zacks Investment Research
Friday, 7 January 2022
17:00	TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference	GlobeNewsWire
Wednesday, 5 January 2022
06:45	TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference	GlobeNewsWire
Wednesday, 20 October 2021
08:23	TCRR Stock: Why It Increased Today	Pulse2
Wednesday, 13 October 2021
06:45	TCR² Therapeutics to Host R&D Day on October 20, 2021	GlobeNewsWire
Friday, 17 September 2021
14:25	TCRR Stock: Why It Significantly Decreased Today	Pulse2
07:30	TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors	GlobeNewsWire
Monday, 13 September 2021
06:45	TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors	GlobeNewsWire
Tuesday, 7 September 2021
06:45	TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference	GlobeNewsWire
Thursday, 2 September 2021
09:19	TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma	GlobeNewsWire
Thursday, 26 August 2021
06:45	TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors	GlobeNewsWire
Tuesday, 17 August 2021
06:45	TCR² Therapeutics Announces Upcoming Medical Meetings Update	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 21 Apr 2023

Adaptimmune Shareholders Can Lock In A Big Merger Spread By Swapping To TCR2 Therapeutics
Seeking Alpha 26 Mar 2023

Adaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic Investors
Seeking Alpha 15 Feb 2023

TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
Seeking Alpha 18 Aug 2022

TCR² Therapeutics: Betting On A Solid Reversal
Seeking Alpha 15 Jun 2021

TCR2 Therapeutics - Promising Technology And Upside Potential

Frequently Asked Questions (FAQ)

When is TCR2 Therapeutics's next earnings date?

Unfortunately, TCR2 Therapeutics's (TCRR) next earnings date is currently unknown.
Does TCR2 Therapeutics pay dividends?

No, TCR2 Therapeutics does not pay dividends.
How much money does TCR2 Therapeutics make?

TCR2 Therapeutics has a market capitalization of 58.10M.
What is TCR2 Therapeutics's stock symbol?

TCR2 Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "TCRR".
What is TCR2 Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of TCR2 Therapeutics?

Shares of TCR2 Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are TCR2 Therapeutics's key executives?
TCR2 Therapeutics's management team includes the following people:
- Dr. Garry E. Menzel M.B.A., Ph.D. Pres, Chief Executive Officer & Director(age: 61, pay: $941,230)
- Dr. Alfonso Quintás Cardama M.D. Chief Medical Officer(age: 54, pay: $678,580)
How many employees does TCR2 Therapeutics have?

As Jul 2024, TCR2 Therapeutics employs 58 workers.
When TCR2 Therapeutics went public?

TCR2 Therapeutics Inc. is publicly traded company for more then 6 years since IPO on 14 Feb 2019.
What is TCR2 Therapeutics's official website?

The official website for TCR2 Therapeutics is tcr2.com.
Where are TCR2 Therapeutics's headquarters?

TCR2 Therapeutics is headquartered at 100 Binney Street, Cambridge, MA.
How can i contact TCR2 Therapeutics?

TCR2 Therapeutics's mailing address is 100 Binney Street, Cambridge, MA and company can be reached via phone at +61 79495200.

TCR2 Therapeutics Inc.

tcr2.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

+61 79495200

100 Binney Street
Cambridge, MA 02142

CIK: 0001750019
ISIN: US87808K1060
CUSIP: 87808K106